Clinical Trial: A 6-week safety and efficacy study of Travatan compared to Xalcom in subjects with open-angle glaucoma(OAG) or ocular hypertension(OHT)


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

A 6-week safety and efficacy study of Travatan compared to Xalcom in subjects with open-angle glaucoma(OAG) or ocular hypertension(OHT)

This study is currently recruiting patients.

Sponsored by:	Alcon Research
Information provided by:	Alcon Research

Purpose

To compare the safety and IOP-lowering efficacy of TRAVATAN and XALCOM in subjects with open-angle glaucoma or ocular hypertension.

Condition	Treatment or Intervention	Phase
Glaucoma, Open-Angle Ocular Hypertension	Drug: Travoprost (0.004%) Drug: Latanoprost (0.005%)/Timolol (0.5%)	Phase IV

MedlinePlus related topics: Eye Diseases; Glaucoma

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title: A 6-week safety and efficacy study of TRAVATAN compared to XALCOM in subjects with open-angle glaucoma or ocular hypertension.

Eligibility

Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both

Criteria

Patients of any race and either sex with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension.

Location and Contact Information

Alcon Clinical +1-817-568-6747 IntlDev@alconlabs.com

Europe, ; Recruiting

More Information

Study ID Numbers: C-01-74
Record last reviewed: January 2003
Record first received: January 3, 2003
ClinicalTrials.gov Identifier: NCT00051155
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-10-22

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services